ReVision Optics Appoints Frank Shields Vice President of Sales Worldwide

Print 25 July 2016

Salesforce recruiting underway in preparation for U.S. launch of Raindrop® Near Vision Inlay in 3Q

LAKE FOREST, Calif.--(BUSINESS WIRE)--ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces the appointment of Frank Shields to the newly created position of Vice President of Sales Worldwide effective immediately. Mr. Shields brings more than 25 years of experience in surgical sales at leading ophthalmic companies and has been instrumental in the launch of several leading ophthalmic lens products. He will be responsible for leading the commercialization of the Raindrop Near Vision Inlay in the U.S. and expanding international sales.

“We are pleased to attract a highly talented professional like Frank to head our sales organization as we shift more focus to commercial operations,” said John Kilcoyne, ReVision Optics President and Chief Executive Officer. “Frank has proven time and again his ability to successfully build sales teams and execute on strategies that produce results. He has first-hand experience in ophthalmic product launches and an established network of key opinion leaders. We are confident that Frank brings the expertise, vision and enthusiasm to lead our U.S. launch and grow sales in international markets.

“We are actively recruiting sales representatives and clinical application specialists to build out our commercial team in preparation for the U.S. launch of the Raindrop inlay in the third quarter. Our newly formed sales organization will target the approximate 2,800 surgeons who perform ophthalmic procedures in the U.S.,” said Mr. Kilcoyne.

The Raindrop Inlay, a microscopic hydrogel inlay designed to correct presbyopia, received U.S. Food and Drug Administration (FDA) approval in late June and is also approved in the European Union, South Korea, Australia and New Zealand.

“This is truly an exciting opportunity and I look forward to working with the team at ReVision Optics to make the Raindrop Inlay a success,” said Mr. Shields. “The Raindrop Inlay provides a compelling solution for the 30 million Americans and millions of others around the world afflicted with presbyopia. Clinical results show significantly improved near vision without loss of binocular distance vision and importantly patients report a very high rate of satisfaction.”

Mr. Shields served at Bausch + Lomb Surgical for 17 years. Most recently as Regional Sales Manager, he assembled and led an ophthalmic surgical sales team that during his tenure achieved the highest market share of that company’s U.S. regions. Previously at Bausch + Lomb, he served as Executive Sales Representative, where he built the firm’s leading revenue-producing territory in the U.S. and supported the launch of several intraocular lens products. While at Bausch + Lomb Surgical, Mr. Shields was recognized for multiple sales achievements including election into the ‘Hall of Fame,’ awarded 13 Platinum Club Wins, and named Regional Business Director of the year and five times as Surgical Sales Representative of the Year. Mr. Shields previously was Senior Surgical Sales Representative at Chiron Vision, where he was instrumental in launching products that helped to create the LASIK market. He began his career as a Surgical Sales Representative at IOLAB, a division of Johnson & Johnson. Mr. Shields is also member of the CEDARS/ASPENS Venture Group, which is comprised of internationally renowned ophthalmic surgeons who back compelling ophthalmic startup projects.

About the Raindrop Near Vision Inlay

The Raindrop Near Vision Inlay is placed in the cornea of the non-dominant eye during a 10-minute procedure. The Raindrop is comprised of approximately 80% water and has a refractive index very similar to the cornea. It is transparent and therefore does not restrict the amount of light reaching the retina. The reshaping of the anterior curvature of the cornea improves near vision.

The Raindrop Near Vision Inlay has received approval by the U.S. Food and Drug Administration, authorization to affix the CE Mark for the European Union, license approval by the Ministry of Food and Drug Safety (South Korea), approval by the Therapeutic Goods Administration (Australia), and registration with the Medicines and Medical Safety Authority (New Zealand). Other country-specific registrations are pending.

About ReVision Optics

ReVision Optics, Inc. focuses on the development and commercialization of innovative optical solutions dedicated to presbyopic vision correction. The company’s Raindrop Near Vision Inlay offers a unique, patented refractive surgery solution. The Raindrop improves near vision that has been lost through the eye’s natural aging process called presbyopia. The Raindrop Near Vision Inlay provides an ideally suited surgical option for near vision enhancement.


All Portfolio


  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news